Compass Therapeutics (CMPX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CMPX Compass Therapeutics

Watchlist

1.490
+0.110+7.97%

Close Nov 22 16:00 ET

1.430
-0.060-4.03%

Post 18:24 ET

205.01MMarket Cap-4257P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Zacks Nov 21 08:40 ET
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Simply Wall StNov 16 07:04 ET
Compass Therapeutics Analyst Ratings
BenzingaNov 15 14:37 ET · Ratings
Leerink Partners Downgrades Compass Therapeutics(CMPX.US) to Hold Rating, Cuts Target Price to $4
Moomoo NewsNov 15 07:33 ET · Ratings
Hold Rating Issued for Compass Therapeutics Amid CTX-009 Uncertainty and Strategic Concerns
TipRanksNov 15 07:25 ET · Ratings
Compass Therapeutics Downgraded to Market Perform From Outperform at Leerink
TipRanksNov 15 07:15 ET · Ratings

Comments

Jaguar8

Oct 4 10:42

NEWS

$Compass Therapeutics (CMPX.US)$
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmaco...

Jaguar8

Apr 16 07:02

$Compass Therapeutics (CMPX.US)$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.

Moomoo Breakfast US

May 4, 2022 07:22

Columns Today's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more

Gainers:
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CMPX Compass Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target